Renal transplant recipients receiving loop diuretic therapy have increased urinary tract infection rate and altered medullary macrophage polarization marker expression

2018 ◽  
Vol 94 (5) ◽  
pp. 993-1001 ◽  
Author(s):  
Janis Casper ◽  
Jessica Schmitz ◽  
Jan Hinrich Bräsen ◽  
Abedalrazag Khalifa ◽  
Bernhard M.W. Schmidt ◽  
...  
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Renal Transplant ◽  
Tract Infection ◽  
Infection Rate ◽  
Loop Diuretic ◽  
Macrophage Polarization ◽  
Diuretic Therapy ◽  
Renal Transplant Recipients ◽  
Transplant Recipients

scholarly journals SP781ANALYSIS OF RISK FACTORS ASSOCIATED WITH URINARY TRACT INFECTION IN RENAL TRANSPLANT RECIPIENTS

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii636-iii636 ◽  
Author(s):  
Alparslan Ersoy ◽  
Nimet Aktas ◽  
Aysegul Oruc ◽  
Bulent Gul ◽  
Abdulmecit Yildiz ◽  
...  
Keyword(s):  
Risk Factors ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Renal Transplant ◽  
Tract Infection ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Factors Associated

scholarly journals Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial

2020 ◽  
Vol 35 (11) ◽  
pp. 1996-2003 ◽  
Author(s):  
Rodrigo Rosado-Canto ◽  
Idalia Parra-Avila ◽  
Javier Tejeda-Maldonado ◽  
Cristopher Kauffman-Ortega ◽  
Francisco T Rodriguez-Covarrubias ◽  
...  
Keyword(s):  
Urinary Tract Infection ◽  
Placebo Group ◽  
Urinary Tract ◽  
Renal Transplant ◽  
Tract Infection ◽  
Asymptomatic Bacteriuria ◽  
Attractive Alternative ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
The Mean

Abstract Background Symptomatic urinary tract infection (UTI) is the most common infectious complication in renal transplant recipients (RTRs). Fosfomycin (FOS) is an attractive alternative for prophylaxis because it does not interact with immunosuppressants; although 90% is excreted unchanged in the urine, it does not require adjustment for renal function for single dose prophylaxis. Methods RTRs were recruited into this randomized, double-blind, placebo-controlled trial. Participants were randomized (1:1) to receive one 4 g dose of FOS disodium intravenously 3 h (FOS group) or placebo (placebo group) before placement and removal of a urinary catheter and before removal of a double-J ureteral stent. All participants received prophylaxis with trimethoprim/sulfamethoxazole. The main outcome was a comparison of the mean number of symptomatic UTI and asymptomatic bacteriuria (AB) episodes per patient during a 7-week follow-up period. The study was registered at ClinicalTrials.gov, NTC03235947. Results Eighty-two participants were included (41 in the FOS group and 41 in placebo group). The mean number of AB or symptomatic UTI episodes per patient was lower in the FOS group [intention-to-treat (ITT) 0.29 versus 0.60, P = 0.04]. The incidence of symptomatic UTI was lower in the FOS group (ITT, 7.3% versus 36.6%, P = 0.001), and there was no difference in the incidence of AB between both groups. The incidence of adverse events was similar in both groups. Conclusions FOS addition is an effective and safe strategy to reduce the number of symptomatic UTIs during the first 7 weeks after renal transplant.

Sign in / Sign up

Export Citation Format

Share Document